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Although GLP-1 has been suggested as a major factor for
the marked improvement of glucose tolerance commonly
seen after sleeve gastrectomy (SG), several observations
challenge this hypothesis. To better understand the role
of GLP-1 in the remission of type 2 diabetes mellitus
(T2DM) long term after SG in humans, we conducted two
separate cross-sectional studies: 1) the GLP-1 response
to a standardized mixed liquid meal (SMLM) was com-
pared in subjects with T2DM antedating SG but with dif-
ferent long-term (>2 years) T2DM outcomes (remission,
relapse, or lack of remission) (study 1) and 2) the effect of
GLP-1 receptor blockade with exendin (9-39) on glucose
tolerance was examined in subjects with T2DM antedat-
ing surgery, who had undergone SG and presented with
long-term T2DM remission (study 2). In study 1, we ob-
served a comparable GLP-1 response to the SMLM re-
gardless of the post-SG outcome of T2DM. In study 2, the
blockade of GLP-1 action resulted in impaired insulin se-
cretion but limited deterioration of glucose tolerance.
Thus, our data suggest the enhanced GLP-1 secretion
observed long term after SG is neither sufﬁcient nor crit-
ical to maintain normal glucose tolerance in subjects with
T2DM antedating the surgery.
GLP-1 has been suggested as a critical mediator for the
marked improvement of glucose tolerance in subjects with
type 2 diabetes mellitus (T2DM) commonly seen after
Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy
(SG) (1). However, this view has been challenged by 1)
studies in humans—performed long after RYGB using the
GLP-1 receptor antagonist exendin (9-39) (Ex 9-39)—
showing that blockade of GLP-1 action results in marked
decrease in insulin secretion but limited impact on glucose
tolerance (2,3); 2) data showing the GLP-1 response to
meal stimuli does not differ between T2DM patients who
after RYGB presented with lack of remission, partial re-
mission, or relapse of T2DM (4); and 3) mouse data dem-
onstrating that whole-body GLP-1 receptor deﬁciency
does not inﬂuence the glycemic response to SG (5).
To gain further insight into the role of GLP-1 in the
remission of T2DM long term after SG in humans, We
conducted two separate cross-sectional studies: 1) we
compared the GLP-1 response to a standardized mixed
liquid meal (SMLM) in subjects with T2DM antedating
SG but with different long-term (.2 years) T2DM out-
comes (remission, relapse, or lack of remission) (study 1)
and 2) we examined the effect of GLP-1 receptor blockade
with Ex 9-39 on glucose tolerance in subjects with T2DM
antedating surgery, who had undergone SG and presented
with long-term T2DM remission (study 2).
RESEARCH DESIGN AND METHODS
Participants in study 1 (n = 23) were selected out of our
series of T2DM patients who had undergone SG at least
2 years before study entry (n = 55), of whom 18 (33%),
31 (56%), and 6 (11%) presented with nonremission, re-
mission, or relapse of T2DM, respectively (6,7). All subjects
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in the relapse group and 10 and 7 subjects from the re-
mission and nonremission group with similar sex distribu-
tion, presurgical BMI, and length of follow-up volunteered
to participate. The GLP-1, glucose, C-peptide, and glucagon
response to a SMLM (398 kcal, 50% carbohydrate, 35%
from fat, 15% protein, Isosource Energy; Novartis, Switzer-
land) challenge were assessed as previously reported (4).
Study 2 was a case-control study involving three
groups of subjects: 1) individuals who had undergone SG
$24 months before inclusion in the study, had pharma-
cologically treated T2DM prior to surgery with duration
of .6 months, and presented T2DM remission at the
time of evaluation (SG-DMR group; n = 8); 2) nondia-
betic individuals who underwent SG $24 months prior
to the study (SG-control group; n = 6); and 3) normal-
weight, nonoperated, healthy subjects (NO-control
group; n = 8). The three groups were matched for age
and sex distribution. The SG-DMR and SG-control
groups were also matched by BMI and length of post-
surgical follow-up. Sample size was calculated to detect
differences among groups with a statistical power of 80%
and an a error of 0.05 based on our previously published
observation of a 10% increase in the area under the
curve of plasma glucose (AUC0–120) during Ex 9-39 versus
saline infusion in control subjects (2) and based on the
expectation of at least a 30% increase in the AUC0–120
with Ex 9-39 versus saline infusion in the SG-DMR group.
The assessment of plasma glucose, insulin, C-peptide, GLP-
1, and gastric inhibitory polypeptide (GIP) to an SMLM,
during Ex 9-39 (Clinalfa Basic; Bachem, Weil am Rhein,
Germany) or saline infusion was performed as previously
described (2).
In both studies, b-cell function parameters were de-
rived from mathematical modeling of plasma glucose
and C-peptide concentrations measured during SMLM,
as previously described (8). Insulin sensitivity was esti-
mated either from fasting plasma insulin and glucose
measurements (homeostasis model assessment of insulin
resistance) or from glucose and C-peptide plasma concen-
trations throughout the SMLM, as described by Matsuda
and DeFronzo (9), using C-peptide instead of insulin as
proposed by Radaelli et al. (10). AUC was calculated using
the trapezoidal method.
Both studies received approval by the hospital ethics
committee. Written informed consent from all participants
was obtained.
Table 1—Clinical and biochemical characteristics and glucose and hormonal responses to a SMLM in participants in study 1
according to glucose tolerance at the time of evaluation
Remission Relapse Nonremission P
n 10 6 7
Age (years) 50.9 6 10.6 59.4 6 13.6 58.7 6 5.5 0.199
Sex (female/male) 7/3 4/2 4/3 0.500
Presurgery BMI (kg/m2) 46.1 6 5.0 44.9 6 5.3 43.1 6 7.2 0.588
T2DM duration (years) 3.8 6 2.1 5.2 6 1.9 12.0 6 6.0*,a 0.002
Presurgery HbA1c [% (mmol/mol)] 6.8 6 1.2 (51 6 13.1) 6.9 6 1.9 (52 6 20.8) 9.4 6 1.9*,
a (79 6 20.8) 0.010
Presurgery insulin treatment (%) 0 17 100*,a ,0.001
BMI at evaluation (kg/m2) 32.7 6 3.0 37.5 6 7.4 32.4 6 4.7 0.149
EWL at evaluation (%) 63 6 15 42 6 27 62 6 11 0.069
HbA1c at evaluation [% (mmol/mol)] 5.1 6 0.3 (32 6 3.3) 6.4 6 0.2* (46 6 2.2) 7.7 6 0.8*,
a (61 6 8.7) ,0.001
Follow-up period (years) 3.0 6 1.0 3.9 6 1.3 3.2 6 0.8 0.216
Fasting glucose (mg/dL) 90 6 8 140 6 42 222 6 79*,a ,0.001
2-h plasma glucose (mg/dL) 106 6 21 186 6 33* 350 6 92*,a ,0.001
AUC0–120 glucose (mg $ dL
21 $min) 16,719 6 2,030 27,487 6 7,304* 40,476 6 10,789*,a ,0.001
AUC0–120 C-peptide (nmol $ L
21 $ min) 312 6 47 289 6 85 190 6 92*,a 0.009
Total insulin output (nmol $ m22) 49 6 8 40 6 13 28 6 13* 0.004
b-Cell glucose sensitivity
(pmol $ min21 $ m22 $ mmol/L21) 86 6 39 38 6 22* 16 6 8* ,0.001
Rate sensitivity (nmol $ m22 $ mmol/L) 1.64 6 1.23 0.48 6 0.60* 0.42 6 0.19* 0.016
Potentiation factor 1.29 6 0.34 1.31 6 0.46 0.83 6 0.20*,a 0.022
IS (mL $ min21 $ m22 ) 3.5 6 1.0 2.1 6 1.2 2.6 6 1.9 0.149
AUC0–120 glucagon
(pg $ dL21 $ min $ 103 ) 8.8 6 2.5 14.1 6 5.6* 13.1 6 2.5 0.014
AUC0–120 GLP-1
(pmol $ L21 $ min $ 103 ) 4.56 6 2.83 4.95 6 1.78 5.06 6 1.37 0.900
Data are means 6 SD. EWL, excess of weight loss; IS, insulin sensitivity. *P , 0.05 compared with remission group. aP , 0.05
compared with relapse group.
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Data are expressed as mean (SD) unless otherwise
speciﬁed. Parametric tests were used in statistical analysis,
as all variables followed Gaussian distribution (Kolmogorov-
Smirnov test, P . 0.05). Paired t test was used for within-
group comparisons in studies with Ex 9-39 or saline. Group
comparisons in study 1 and study 2 were performed using
ANOVA with post hoc analysis. In study 2, parameters
obtained during Ex 9-39 or saline infusions were compared
among groups using two-way ANOVA for repeated mea-
sures. Statistical analysis was performed using SPSS 17.0.
Statistical signiﬁcance was set at P , 0.05.
RESULTS
Study 1
As shown in Table 1 and Supplementary Fig. 1, the glu-
cose response to the SMLM challenge differed among
groups (P , 0.001). In addition, b-cell glucose and rate
sensitivity were impaired in relapsing and nonremitting
patients—to a larger extent in the latter in whom total
insulin output and potentiation were also lower than in
the remission group. Of note, no differences were found
among the three groups in the GLP-1 AUC0–120 or the
GLP-1 concentrations during the test. In contrast, the
glucagon response was signiﬁcantly enhanced in relapsing
and nonremitting patients alike compared with patients
who were in remission.
Study 2
The clinical features of participants in study 2 are shown
in Table 2. Time since surgery ranged from 2.0 to 5.2
years. As shown in Fig. 1 and Table 3, patients in the
SG-control group had slightly lower fasting glucose levels
than the SG-DMR (P = 0.013) or NO-control group. Ex 9-
39 infusion was associated with a signiﬁcant increase in
fasting glucose, similarly in the three groups. Meal inges-
tion gave rise to similar peak and 2-h glucose levels in the
three groups. GLP-1 blockade was associated with higher
and earlier glucose peak, higher 2-h glucose, higher mean
glucose, and greater glucose AUC0–120, with no differences
in the magnitude of the effect across groups. This was also
true of the incremental glucose AUCs during the meal.
Fasting insulin levels did not differ across groups and
were not inﬂuenced by Ex 9-39. As expected from their
higher glucose levels, individuals in the SG-DMR group
presented with higher fasting insulin secretion rates
than the SG-control group; however, Ex 9-39 had no effect
on this parameter. Total insulin output did not differ among
groups prior to Ex 9-39 infusion, but Ex 9-39 was associ-
ated with a blunted insulin response in both SG groups
compared with the NO-control group (Pinteraction = 0.040).
In the SG-DMR group, Ex 9-39 resulted in decreased b-cell
glucose sensitivity (P = 0.013) but no signiﬁcant change in
the potentiation factor or rate sensitivity.
Prior to meal ingestion, Ex 9-39 had no effect on
glucagon or GIP plasma concentrations but was associated
with a signiﬁcant increase in GLP-1 in the three groups
(P , 0.001) with no treatment-group interaction (P =
0.793) (Supplementary Table 1 and Supplementary
Fig. 2). As expected, meal ingestion per se elicited
a higher GLP-1 response in the two surgical groups com-
pared with the NO-control group (P = 0.015), which was
not coupled to a suppression of the glucagon response
(Supplementary Fig. 2). Ex 9-39 was associated with
a further increase in the GLP-1 response in all groups
(P , 0.001), which was associated with increases in the
glucagon response.
DISCUSSION
Our data show that 1) the striking GLP-1 response to
meal intake observed long term after SG is not sufﬁcient
to maintain normal glucose tolerance in subjects with
T2DM antedating the surgery and 2) that in subjects
with surgically induced long-term T2DM remission, block-
ade of GLP-1 action results in limited deterioration of
glucose tolerance. Thus, our results strongly suggest
Table 2—Clinical features of participants in study 2
NO-control group SG-control group SG-DMR group P
n 8 6 8
Age (years) 50.0 6 13.0 52.1 6 13.1 49.8 6 12.4 0.936
Sex (female/male) 6/2 4/2 6/2 0.926
Presurgery BMI (kg/m2) — 44.9 6 5.3 47.7 6 5.5 0.506
T2DM duration (years) — — 2.8 6 1.8
Presurgery HbA1c [% (mmol/mol)] — 5.0 6 0.3 (31 6 3.3) 7.1 6 2.1 (54 6 23.0) 0.025
BMI at evaluation (kg/m2) 23.3 6 2.0 31.1 6 4.2* 32.7 6 2.3* ,0.001
EWL at evaluation (%) — 75 6 19 64 6 16 0.265
Fasting plasma glucose (mg/dL) 88 6 7 81 6 11 91 6 8 0.086
HbA1c at evaluation [% (mmol/mol)] 5.5 6 0.3 (37 6 3.3) 5.4 6 0.4 (36 6 4.4) 5.3 6 0.2 (34 6 2.2) 0.369
HOMA-IR 1.3 6 0.8 1.4 6 0.8 2.4 6 0.6 0.021
Time of postsurgical follow-up (years) — 2.9 6 0.9 3.4 6 0.9 0.433
Data are expressed as means6 SD. EWL, excess of weight loss; HOMA-IR, homeostasis model assessment of insulin resistance. *P ,
0.05 compared with NO-control group.
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that enhanced GLP-1 secretion commonly described after
SG is not the key determinant of the long-term beneﬁcial
effects of this type of surgery on T2DM.
Because of the well-established role of GLP-1 in glucose
homeostasis and the parallel improvement in glucose
tolerance, b-cell function, and GLP-1 response after SG in
several association studies, a causative role of GLP-1 in
the amelioration of glucose homeostasis commonly seen
after SG has been proposed (1,11,12). According to this
hypothesis, a larger incretin response should have been
observed in SG subjects in remission in our study 1
compared with those with lack of T2DM remission. In
contrast, in study 1, GLP-1 release was almost superim-
posable regardless of glucose tolerance status. Admittedly,
postsurgical restoration of the GLP-1 response was an
independent determinant of restored glucose tolerance
in a recent prospective study of T2DM patients who
had undergone SG or RYGB (11). Nonetheless, in line
with our data, in that study the postsurgical GLP-1
response was not an independent predictor of glucose
tolerance status. We also acknowledge data obtained in
rodents suggesting that differences in the sensitivity to
GLP-1 could be implicated in the effects of RYGB on
glucose tolerance (13). Nonetheless, though limited by
our cross-sectional design, the current association study
supports the notion that GLP-1 secretion does not play
a critical role in the outcome of T2DM after SG.
To circumvent the limitations inherent in association
studies, we conducted study 2, in which glucose tolerance
was evaluated with or without GLP-1 blockade. In support
of the ﬁndings in study 1, GLP-1 blockade resulted in
limited deterioration of glucose tolerance. In particular, in
subjects in remission of T2DM the blockade resulted in
only a 13.2 6 15.9% increase in the glucose response,
similar to the change seen in the NO-control group
(10.1 6 8.4%) (P = 0.281) (Table 3). These results are
similar to those recently reported by our group and others
in subjects in T2DM remission after RYGB (2,14).
Figure 1—Blood glucose and insulin secretion in response to a SMLM during saline (□) or Ex 9-39 (◆) infusion in normal-weight NO-
control subjects (A), nondiabetic SG-control subjects (B), and SG-DMR subjects (C ). Data are presented as mean 6 SEM. *P < 0.05
relative to the saline condition.
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Importantly, our subjects with postsurgical remission were
also compared with a nondiabetic group that had undergone
SG, thereby excluding anatomical differences as a potential
source of confounding. Although the use of a mixed-meal
challenge rather than a standard oral glucose tolerance test
precluded formal assessment of glucose tolerance, under
Ex 9-39 infusion only one of eight patients each in the
SG-DMR and the NO-control group presented with 2-h
glucose levels above the diagnostic threshold for T2DM.
In agreement with previous studies, in our studies
b-cell function emerged as the dominant factor inﬂuenc-
ing the outcome at 2 years after surgery (11). The impair-
ment in b-cell function found in study 1 is concordant
with the altered insulin secretion after a meal challenge as
well as intravenous glucose administration previously
reported by our group in subjects who had undergone
RYGB (4). Although the b-cell response to other stimuli
was not tested in the current study, recent evidence con-
sistently shows that residual b-cell function is required
for a sustained beneﬁcial effect of RYGB on glucose tol-
erance even in the context of marked GLP-1 secretion
(15). Of note, in study 2 Ex 9-39 was associated with
a signiﬁcant decrease in insulin secretion and total insulin
output in both surgical groups, supporting the notion that
GLP-1 does potentiate insulin secretion after SG and
RYGB (16). Nonetheless, the limited impact of the GLP-1
blockade on both insulin secretion and glucose tolerance
after SG suggests that other factors are important.
Rapid gastric emptying could be viewed as a potentially
unifying mechanism for the hormonal changes after SG.
In a recent study in a rodent model, Chambers et al. (17)
demonstrated that SG causes accelerated emptying of gas-
tric contents into the intestine and failure to respond to
many of the regulatory signals that normally control gas-
tric emptying rate, including GLP-1. On the other hand,
postprandial hyperglucagonemia, such as that found in
our studies (11,12), has also been described after pharma-
cological or surgical acceleration of gastric emptying in
human subjects (18,19). Although the mechanism(s) under-
lying this phenomenon remain unclear, it has been hypoth-
esized that rapid increases in portal vein glycemia—due to
accelerated intestinal glucose ﬂux—could activate portal
glucose sensors inﬂuencing neural regulation of a-cell
activity (20). Under these circumstances, the enhanced
GLP-1 response after SG could be aimed not only, or
not so much, to potentiate insulin secretion but also, or
primarily, to restore gastric motility. On the other hand,
the paradoxical rise in glucagon release in SG-operated sub-
jects may result from signal(s) overriding the normal regu-
lation of the a-cell, which our Ex 9-39 results suggest is at
least partly retained postsurgery.
Within its limitations (the cross-sectional design, use
of a mixed meal rather than an oral glucose tolerance test,
lack of measures of gastric emptying, and other physio-
logical determinants of glucose tolerance), the current
study is the ﬁrst to analyze the contribution of GLP-1 to
glucose tolerance after SG using an outcome and a GLP-1
blockade protocol. Although our data do not rule out a role of
GLP-1 in improving glucose tolerance shortly after surgery
(11,12) and sustaining weight loss (21), they strongly suggest
Table 3—Glucose and insulin responses to a SMLM with or without Ex 9-39
NO-control group (n = 8) SG-control group (n = 6) SG-DMR group (n = 8)
Pgroup PEx 9-39Saline Ex 9-39 Saline Ex 9-39 Saline Ex 9-39
Glucose at 230 min (mg/dL) 88 6 7 93 6 5 81 6 11 81 6 13 91 6 8 92 6 8 ,0.019 0.444
Glucose at 0 min (mg/dL) 92 6 6 101 6 9 84 6 8 91 6 10 92 6 8 100 6 12 0.130 ,0.001
Peak glucose (mg/dL) 149 6 28 170 6 36 149 6 39 150 6 37 178 6 18 196 6 15 0.176 0.013
Time to peak glucose (min) 68 6 26 56 6 29 43 6 20 32 6 16 53 6 10 38 6 6 0.066 0.032
2-h glucose (mg/dL) 118 6 25 133 6 45 90 6 29.5 105 6 39 114 6 31 141 6 31 0.206 0.008
Mean glucose (mg/dL) 123 6 18 135 6 17 114 6 28 118 6 35 139 6 32 156 6 36 0.817 0.018
AUC glucose0–120
(mg $ dL21 $ min $ 103) 14.9 6 2.2 16.3 6 2.0 14.0 6 3.4 14.4 6 4.3 17.0 6 1.4 19.1 6 1.6 0.124 0.005
Insulin at 230 min (pmol/L) 45 6 24 55 6 43 51 6 25 38 6 19 77 6 19 63 6 22 0.142 0.232
Insulin at 0 min (pmol/L) 35 6 19 47 6 35 34 6 16 36 6 18 49 6 13 45 6 12 0.521 0.275
Mean insulin (pmol/L) 239 6 110 243 6 93 492 6 228 350 6 95 400 6 158 309 6 122 0.023 0.039
Fasting ISR
(pmol $ min21 $ m22) 69 6 28 72 6 26 50 6 18 53 6 13 88 6 14 80 6 14 0.013 0.892
Total insulin output
(nmol $ m22) 41 6 12 42 6 8 36 6 8 32 6 8 49 6 11 40 6 11 0.132 0.017
b-Cell glucose sensitivity 151 6 100 100 6 56 91 6 29 94 6 42 120 6 72 73 6 46 0.512 0.008
Rate sensitivity
(nmol $ m22 $ mmol/L) 1.85 6 1.62 1.30 6 0.65 1.41 6 1.02 1.48 6 0.95 2.38 6 1.08 2.27 6 1.29 0.234 0.517
Potentiation factor 1.02 6 0.40 1.31 6 0.65 1.40 6 1.01 1.48 6 0.95 1.50 6 0.32 1.37 6 0.56 0.725 0.909
Data are expressed as means 6 SD. ISR, insulin secretion rate.
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that at a time when weight loss after SG has occurred, the
impact of GLP-1 on glucose tolerance is limited.
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